Feb 17, 2021 10:04AM
Feb 6, 2020 07:00AM
Feb 6, 2020 07:00AM
Jan 23, 2020 07:00AM
Jan 7, 2020 07:00AM
Nov 4, 2019 07:00AM
Oct 11, 2019 07:00AM Half-year report
Oct 7, 2019 07:00AM
Oct 3, 2019 07:00AM
Jun 18, 2019 07:00AM
Feb 13, 2019 02:00AM
Nov 1, 2018 03:00AM
Oct 3, 2018 03:00AM
Aug 16, 2018 07:00AM Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Aug 2, 2018 02:00PM
Apr 20, 2018 07:00AM
Apr 19, 2018 07:00AM
Apr 11, 2018 07:00AM
Mar 14, 2018 07:00AM
Mar 7, 2018 07:00AM
Feb 26, 2018 07:00AM Summit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
Jan 25, 2018 07:07AM
Jan 25, 2018 07:00AM
Dec 21, 2017 02:00AM
Nov 20, 2017 07:05AM
Nov 20, 2017 07:00AM
Nov 9, 2017 07:00AM
Oct 9, 2017 07:00AM Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017
Oct 4, 2017 07:00AM
Sep 25, 2017 07:00AM
Sep 11, 2017 07:00AM
Sep 5, 2017 07:02AM
Sep 5, 2017 07:00AM
Jun 22, 2017 07:03AM
Jun 22, 2017 07:00AM Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
Jun 5, 2017 07:00AM
May 15, 2017 07:10AM
May 15, 2017 07:00AM
Apr 28, 2017 06:30PM
Mar 29, 2017 07:00AM
Mar 27, 2017 07:00AM
Feb 28, 2017 07:00AM Summit Therapeutics Recognises 10th Annual Rare Disease Day
Feb 1, 2017 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All